Skip to main navigation Skip to search Skip to main content

Neuronal Cell Differentiation of iPSCs for the Clinical Treatment of Neurological Diseases

  • Dong Hun Lee
  • , Eun Chae Lee
  • , Ji young Lee
  • , Man Ryul Lee
  • , Jae Won Shim
  • , Jae Sang Oh
  • The Catholic University of Korea
  • The Catholic University of Korea, College of Medicine
  • Uijeongbu St. Mary's Hospital
  • Soonchunhyang University

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Current chemical treatments for cerebrovascular disease and neurological disorders have limited efficacy in tissue repair and functional restoration. Induced pluripotent stem cells (iPSCs) present a promising avenue in regenerative medicine for addressing neurological conditions. iPSCs, which are capable of reprogramming adult cells to regain pluripotency, offer the potential for patient-specific, personalized therapies. The modulation of molecular mechanisms through specific growth factor inhibition and signaling pathways can direct iPSCs’ differentiation into neural stem cells (NSCs). These include employing bone morphogenetic protein-4 (BMP-4), transforming growth factor-beta (TGFβ), and Sma-and Mad-related protein (SMAD) signaling. iPSC-derived NSCs can subsequently differentiate into various neuron types, each performing distinct functions. Cell transplantation underscores the potential of iPSC-derived NSCs to treat neurodegenerative diseases such as Parkinson’s disease and points to future research directions for optimizing differentiation protocols and enhancing clinical applications.

Original languageEnglish
Article number1350
JournalBiomedicines
Volume12
Issue number6
DOIs
StatePublished - Jun 2024

Bibliographical note

Publisher Copyright:
© 2024 by the authors.

Keywords

  • BMP-4 protein
  • SMAD proteins
  • induced pluripotent stem cells
  • neural stem cells
  • transforming growth factor beta
  • transplantation

Fingerprint

Dive into the research topics of 'Neuronal Cell Differentiation of iPSCs for the Clinical Treatment of Neurological Diseases'. Together they form a unique fingerprint.

Cite this